ASCVD Risk Assessment and Management Using the ASCVD Risk Calculator
The ASCVD risk calculator is an essential tool for estimating 10-year risk of atherosclerotic cardiovascular disease events and guiding preventive therapy decisions, particularly statin therapy in primary prevention. 1
What is the ASCVD Risk Calculator?
- The American College of Cardiology/American Heart Association ASCVD risk calculator (Risk Estimator Plus) estimates the 10-year risk of atherosclerotic cardiovascular disease events including myocardial infarction, stroke, and cardiovascular death 1
- Available online at tools.acc.org/ASCVD-Risk-Estimator-Plus 1
- The calculator incorporates traditional risk factors including age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure treatment status, diabetes, and smoking status 1
Risk Categories and Their Interpretation
The 2018 AHA/ACC guidelines categorize 10-year ASCVD risk into four levels:
Using ASCVD Risk to Guide Management
Statin Therapy Recommendations
- High risk (>20%): Statin therapy strongly recommended 1
- Intermediate risk (7.5% to <20%): Statin therapy should be considered after clinician-patient risk discussion 1
- Borderline risk (5% to <7.5%): Consider statin therapy in selected patients with risk-enhancing factors 1
- Low risk (<5%): Generally lifestyle management only 1
Risk Refinement Strategies
When risk assessment is uncertain, particularly in borderline or intermediate risk patients:
Consider risk-enhancing factors 1, 2:
- Family history of premature ASCVD
- Persistent elevated LDL-C ≥160 mg/dL
- Chronic kidney disease
- Metabolic syndrome
- Inflammatory conditions
- High-sensitivity C-reactive protein ≥2.0 mg/L
- Lipoprotein(a) ≥50 mg/dL
- Apolipoprotein B ≥130 mg/dL
Coronary Artery Calcium (CAC) scoring 1:
- CAC = 0: Consider withholding or deferring statin therapy (except in diabetics, smokers, or those with strong family history)
- CAC 1-99: Favors statin therapy
- CAC ≥100 or ≥75th percentile for age/sex: Strongly favors statin therapy
- CAC is particularly useful for reclassifying risk in intermediate-risk patients 1
Special Populations
Diabetes
- Diabetes is included in the risk calculator as a risk factor 1
- The calculator does not account for diabetes duration or complications such as albuminuria 1
- For individuals with diabetes and hypertension at higher cardiovascular risk (existing ASCVD or 10-year ASCVD risk ≥15%), a blood pressure target of <130/80 mmHg may be appropriate 1
- For those with diabetes and hypertension at lower risk (10-year ASCVD risk <15%), a blood pressure target of <140/90 mmHg is recommended 1
Limitations and Considerations
- Risk calculators are bound by the underlying data that informs them and may become less accurate as population health changes 1
- There is variability in calibration across subgroups including sex, race, and diabetes status 1
- Traditional risk factors are strong population-based markers but poor individual discriminators of coronary atherosclerotic disease 1
- The new PREVENT equations (2023) tend to estimate lower risk compared to the older Pooled Cohort Equations, which may reduce the number of adults eligible for statin therapy 3
Practical Application in Clinical Practice
- Calculate 10-year ASCVD risk using the Risk Estimator Plus tool 1
- Categorize risk level (low, borderline, intermediate, high) 1
- Consider risk-enhancing factors if risk is borderline or intermediate 1, 2
- Consider CAC scoring for further risk stratification when the decision about statin therapy remains uncertain 1
- Engage in shared decision-making with the patient about preventive strategies 1
- Implement appropriate therapy based on risk level:
Common Pitfalls to Avoid
- Relying solely on the risk calculator without considering other clinical factors 1
- Using CAC scoring in symptomatic patients (not recommended) 1
- Failing to reassess risk periodically as risk factors may change over time 1
- Not engaging patients in shared decision-making about preventive strategies 1
- Overlooking the importance of lifestyle modifications regardless of pharmacological therapy 1